Spanish Competition Authority Latest to Confirm Competition Investigation Against Pharmaceutical Firm Leadiant
- 22/12/2020
- Articles
Reports that Leadiant is also in the crosshairs of the Spanish competition authority were confirmed today. The Comisión Nacional de los Mercados y la Competencia announced that it started formal proceedings against Leadiant Biosciences Spa and Leadiant Biosciences LTD on the grounds that these firms may have abused an allegedly dominant position on the relevant market (see, attached press release).
If the proceedings already under way against Leadiant in Belgium, Italy and The Netherlands are any indication, then Leadiant will now also have to explain the pricing policy which it applies in Spain for chenodeoxycholic acid Leadiant (CDCA), a medicine indicated for the treatment of patients afflicted with cerebrotendinous xanthomatosis, a rare metabolic disorder, and designated as an orphan medicine in December 2014. Leadiant may also have to answer for other allegedly abusive practices (see, Van Bael & Bellis Life Sciences News Alerts of 3 November 2020, 29 June 2020, 16 October 2019, 17 September 2019, 9 September 2019, 9 April 2019 and 11 February 2019).
